[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse IFNAR1

Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Single-pass type I membrane protein Late endosome Lysosome Note=Interferon binding triggers internalization of the receptor from the cell membrane into endosomes and then into lysosomes.
Domain PF09294 Interferon-alpha/beta receptor
PF01108 Tissue factor
Function

Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1 (PubMed:2153461, PubMed:7665574, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:21854986). Functions in general as heterodimer with IFNAR2 (PubMed:7665574, PubMed:10049744, PubMed:21854986). Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves (PubMed:7665574, PubMed:21854986). Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity).

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0007159 leukocyte cell-cell adhesion
GO:0007259 JAK-STAT cascade
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032606 type I interferon production
GO:0032608 interferon-beta production
GO:0032609 interferon-gamma production
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032648 regulation of interferon-beta production
GO:0032649 regulation of interferon-gamma production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032728 positive regulation of interferon-beta production
GO:0032729 positive regulation of interferon-gamma production
GO:0032731 positive regulation of interleukin-1 beta production
GO:0032732 positive regulation of interleukin-1 production
GO:0034340 response to type I interferon
GO:0035455 response to interferon-alpha
GO:0035457 cellular response to interferon-alpha
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042110 T cell activation
GO:0045088 regulation of innate immune response
GO:0045351 type I interferon biosynthetic process
GO:0050663 cytokine secretion
GO:0050701 interleukin-1 secretion
GO:0050702 interleukin-1 beta secretion
GO:0050704 regulation of interleukin-1 secretion
GO:0050706 regulation of interleukin-1 beta secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050716 positive regulation of interleukin-1 secretion
GO:0050718 positive regulation of interleukin-1 beta secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051607 defense response to virus
GO:0060337 type I interferon signaling pathway
GO:0060338 regulation of type I interferon-mediated signaling pathway
GO:0060759 regulation of response to cytokine stimulus
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071357 cellular response to type I interferon
GO:0071593 lymphocyte aggregation
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0004896 cytokine receptor activity
GO:0004904 interferon receptor activity
GO:0004905 type I interferon receptor activity
GO:0019955 cytokine binding
GO:0019961 interferon binding
GO:0019962 type I interferon binding
Cellular Component GO:0005770 late endosome
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-912694: Regulation of IFNA signaling
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IFNAR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IFNAR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28196594Colorectal CarcinomaPromote immunityGenetic stabilization of IFNAR1 improved CTL survival and increased the efficacy of the chimeric antigen receptor T cell transfer and PD-1 inhibition.
28723893MelanomaPromote immunity; increase the efficacy of immunotherapyWe confirmed this finding in an in vivo competitive assay that compared the relative growth of mixtures of isogenic Stat1-null or control B16 cells in animals treated with immunotherapy (Fig. 1f). In wild-type mice treated with GVAX and anti-PD-1 immunotherapy, the relative proportion of Stat1-null cells increased significantly (Fig. 1g, h; P < 0.01, Student’s t-test), suggesting that Stat1-null cells have a marked growth advantage over wild-type tumour cells when under immune attack. Similar results were obtained for Jak1-null and Ifngr1-null cells (Fig. 1h).
29622580breast carcinomaPromote immunityIFNAR-neuT tumors exhibited deregulation of genes having adverse prognostic value in breast cancer patients, including the breast cancer stem cell (BCSC) marker aldehyde dehydrogenase-1A1 (ALDH1A1).
20233880Prostate CarcinomaPromote immunityLike TLR3(-/-) mice, IFN-alpha receptor 1 (IFNAR1)(-/-) mice exhibited reduced tumor surveillance and impaired tumor suppression following polyI:C treatment.
21930769FibrosarcomaPromote immunityWe further show that mice lacking IFNAR1 (IFN-α/β receptor 1) in dendritic cells (DCs; Itgax-Cre(+)Ifnar1(f/f) mice) cannot reject highly immunogenic tumor cells and that CD8α(+) DCs from these mice display defects in antigen cross-presentation to CD8(+) T cells
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IFNAR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.42; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 9.02; FDR: 0.000 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 7.37; FDR: 0.000 Sensitive to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IFNAR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1360.664
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0970.957
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1660.9
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1150.745
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0960.954
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.390.864
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.010.982
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0020.999
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0310.988
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2020.889
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0320.625
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0880.192
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IFNAR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IFNAR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IFNAR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IFNAR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IFNAR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IFNAR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IFNAR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIFNAR1
Nameinterferon (alpha, beta and omega) receptor 1
Aliases IFRC; IFNAR; IFNBR; CRF2-1; IFN-R-1; IFN-alpha/beta receptor 1; alpha-type antiviral protein; beta-type anti ......
Chromosomal Location21q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IFNAR1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IFNAR1.
ID Name Drug Type Targets #Targets
DB00008Peginterferon alfa-2aBiotechIFNAR1, IFNAR22
DB00011Interferon alfa-n1BiotechIFNAR1, IFNAR22
DB00018Interferon alfa-n3BiotechIFNAR1, IFNAR22
DB00022Peginterferon alfa-2bBiotechIFNAR1, IFNAR22
DB00034Interferon Alfa-2a, RecombinantBiotechIFNAR1, IFNAR22
DB00060Interferon beta-1aBiotechIFNAR1, IFNAR22
DB00068Interferon beta-1bBiotechIFNAR1, IFNAR22
DB00069Interferon alfacon-1BiotechIFNAR1, IFNAR22
DB00105Interferon Alfa-2b, RecombinantBiotechIFNAR1, IFNAR22
DB05258Natural alpha interferonBiotechIFNAR11
DB05472omega interferonSmall MoleculeIFNAR1, IFNAR22